News

Ozempic maker Novo Nordisk on track for its worst day since Black Monday
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Wegovy maker Novo's profit warning triggers $70 billion share rout
Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...
Novo Nordisk shares plunge 17% after Wegovy-maker cuts full-year guidance
Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth expectations for its Wegovy obesity drug in the key U.S. market. Shares were down ...
Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
24/7 Wall St.1h
Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing
Novo Nordisk A/S stock dips after 2025 guidance cut. However, click for why NVO's strong GLP-1 prospects, growing pipeline, ...
Novo Nordisk Cuts Earning Forecasts Again, Names New CEO
Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday ...
Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
Novo Nordisk Cuts Guidance as Copycat Versions of Wegovy Hurt Results
The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S.